|Bid||159.00 x 900|
|Ask||171.00 x 800|
|Day's Range||165.90 - 170.00|
|52 Week Range||101.81 - 178.64|
|Beta (5Y Monthly)||1.06|
|PE Ratio (TTM)||39.70|
|Earnings Date||May 04, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||202.53|
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (the "Company" or "Jazz") today announced the pricing of the previously announced offering (the "Offering") of $1.5 billion in an aggregate principal amount of 4.375% senior secured notes due 2029 (the "Notes") by Jazz Securities Designated Activity Company, a direct wholly owned subsidiary of the Company (the "Issuer"). The Notes will mature on January 15, 2029 and will bear an interest rate of 4.375%. The Notes will be guaranteed by the Company and certain of its subsidiaries. The Offering is expected to close on April 29, 2021 subject to customary closing conditions.
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
Rating Action: Moody's assigns Ba2 to Jazz Pharma's secured notes; negative outlookGlobal Credit Research - 20 Apr 2021New York, April 20, 2021 -- Moody's Investors Service ("Moody's") assigned a Ba2 rating to the new senior secured notes issuance of Jazz Securities Designated Activity Company, a subsidiary of Jazz Pharmaceuticals plc (collectively "Jazz"). There are no changes to the existing ratings of the company, including the Ba3 Corporate Family Rating, the Ba3-PD Probability of Default Rating, or the SGL-1 Speculative Grade Liquidity Rating. The outlook remains unchanged at negative.Proceeds of the notes, together with secured credit facilities, cash on hand, and equity will be used to fund the acquisition of GW Pharmaceuticals along with the various fees and expenses for approximately $6.7 billion net of cash acquired.Ratings assigned:..Jazz Securities Designated Activity Company:Guaranteed Senior secured notes, assigned Ba2 (LGD3)RATINGS RATIONALEJazz's Ba3 rating reflects the company's position as a specialized pharmaceutical company with approximately $2.9 billion of pro forma revenue including GW Pharmaceuticals.